Kezar Life Sciences Reports $5.8 Million Net Loss in Q1 2026, Announces Merger with Aurinia Pharma

Kezar Life Sciences, Inc. reported a net loss of $5.8 million for the first quarter of 2026, a significant improvement compared to a net loss of $16.6 million during the same period in 2025. The company's total operating expenses decreased to $7.4 million from $17.7 million year-over-year, primarily due to a reduction in research and development costs, which fell from $12.2 million to $1.5 million. This decline was attributed to the completion of clinical trials and a strategic decision to terminate the PALIZADE trial, alongside a workforce reduction that cut personnel-related expenses.

In terms of financial position, Kezar's cash and cash equivalents stood at $66.2 million as of March 31, 2026, down from $71.9 million at the end of 2025. The company has an accumulated deficit of $496.3 million, reflecting ongoing operational losses since its inception. The decrease in cash was influenced by cash used in operating activities, which amounted to $7.4 million for the quarter, compared to $17.2 million in the prior year. The company anticipates that its existing cash will be sufficient to meet its operational needs for at least the next 12 months.

Strategically, Kezar Life Sciences is in the process of a merger with Aurinia Pharma U.S., Inc., which was announced on March 30, 2026. The merger agreement includes a cash tender offer of $6.955 per share, plus a contingent value right for additional payments based on future milestones. The offer commenced on April 13, 2026, and is subject to various conditions, including the tender of a majority of outstanding shares. The company has also entered into an asset purchase agreement with Enodia Therapeutics, resulting in an upfront payment of $1 million and potential future milestone payments totaling up to $127 million.

Operationally, the company has undergone significant restructuring, including a workforce reduction of approximately 70% in late 2025, which has led to restructuring charges of $0.6 million in the first quarter of 2026. This restructuring is part of a broader strategy to explore alternatives aimed at maximizing shareholder value. The company has also terminated its lease agreement for its corporate headquarters, incurring a one-time payment of $2 million to fulfill its remaining obligations.

Looking ahead, Kezar Life Sciences expects to continue incurring losses as it navigates the merger process and evaluates its strategic options. The company has indicated that it may pursue additional financing to support its operations and meet its obligations, emphasizing the uncertainty surrounding the completion of the merger and the potential need for further capital.